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ABSTRACT 61 
 62 
Primary ovarian insufficiency (POI) affects 1% of women before 40 years. The recent leap in 63 
genetic knowledge obtained by next-generation sequencing (NGS) together with animal models 64 
has further elucidated its molecular pathogenesis, identifying novel genes/pathways. Mutations 65 
of >60 genes emphasize high genetic heterogeneity. Genome-wide association studies have 66 
revealed a shared genetic background between POI and reproductive aging. NGS will provide a 67 
genetic diagnosis leading to genetic/therapeutic counseling: first, defects in meiosis or DNA 68 
repair genes may predispose to tumors; second, specific gene defects may predict the risk of 69 
rapid loss of a persistent ovarian reserve, an important determinant in fertility preservation. 70 
Indeed, a recent innovative treatment of POI by in vitro activation of dormant follicles proved 71 
successful.  72 
 73 
KEY WORDS 74 
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dormant follicles. 76 
 77 
GLOSSARY  78 
Anti-Müllerian hormone (AMH): a growth factor produced by the granulosa cells of growing 79 
follicles. Serum AMH level is an indirect marker of the ovarian reserve and declines with 80 
increasing age.  81 
Follicle-stimulating hormone (FSH): a pituitary-derived hormone that stimulates estrogen 82 
production, follicle growth and selection of the preovulatory follicle. Serum FSH levels are 83 
elevated upon ovarian aging due to the loss of negative feedback signals. Normal FSH 84 
concentrations (IU/L) are: during follicular phase: 3.5-9.0; ovulatory phase: 7.0-21.5; luteal 85 
phase: 1.7-7.0; post-menopause: 26-140.                            86 
  87 
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Homologous recombination (HR): a process that assures faithful repair of double strand 88 
breaks, one of the most dangerous DNA damages. HR relies on the invasion of a similar DNA 89 
matrix (the homologous chromosome during meiosis) as a template to repair the broken DNA. 90 
The products of this repair can either be a local replacement of DNA sequence or exchange of 91 
large chromosome fragments, respectively termed non-crossover and crossover. The meiotic 92 
crossovers are mandatory for proper segregation of chromosomes and thus halving precisely the 93 
genome in gametes. 94 
In vitro activation of small follicles: Although menstrual cycles cease in POI patients, some of 95 
them retain residual dormant ovarian follicles. A new infertility treatment has been developed, 96 
which enables POI patients to conceive using their own eggs by activation of the residual 97 
dormant follicles by in vitro manipulation of signaling pathways responsible for follicular 98 
quiescence. 99 
Luteinizing hormone (LH): a pituitary-derived hormone that triggers ovulation. Serum LH 100 
levels increase upon ovarian aging due to the loss of negative feedback signals. 101 
Meiosis: Meiosis is the universal cellular process in eukaryotes that allows forming the haploid 102 
reproductive cells. 103 
Meiotic DNA double strand breaks (DSB): DSBs are programmed DNA breaks generated 104 
early during prophase I and catalyzed by the sporulation 11 homolog (SPO11) enzyme. DSBs are 105 
concentrated in “hotspots” designated by PR domain containing 9 (PRDM9) through the 106 
deposition of trimethylation on lysine 4 of histone 3. 107 
Next generation sequencing (NGS) also known as high-throughput sequencing, describes 108 
modern sequencing technologies that allow the sequencing of thousands to millions of DNA 109 
molecules simultaneously. It allows sequencing multiple genes and multiple individuals at the 110 
same time. 111 
Non-homologous end joining (NHEJ): A DSB repair pathway often opposed to HR. NHEJ 112 
directly ligates broken DNA ends together. It is believed to result in low repair fidelity in the 113 
absence a homologous sequence to guide DNA repair as in HR. 114 
Ovarian reserve (OR): a term describing the quality and number of resting oocytes within 115 
primordial follicles, and considered as a female’s reproductive potential. 116 
PI3K/Akt pathway: the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin 117 
(PI3K/Akt/mTOR) signaling pathway regulating various stages of folliculogenesis. Studies in 118 
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most genetic mouse models have revealed an essential role of this pathway in primordial follicle 119 
activation. 120 
Primordial germ cells (PGCs): The primary cells that form the progenitors of gametes. PGCs 121 
will populate the embryonic gonads and differentiate into either oocytes or spermatocytes.  122 
Whole exome sequencing (WES): Sequencing by NGS the protein-coding region of the human 123 
genome (exome) that represents <2% of the genome, but contains most known disease-related 124 
variants.  125 
 126 
INTRODUCTION   127 
Primary ovarian insufficiency (POI), affects 1% of women before 40 years’ age, being thus a 128 
relatively frequent syndrome [1]. POI is often diagnosed too late, causing irreversible impairment 129 
of fertility and well-being of the affected women. Recent data indicate that POI is associated 130 
with significant morbidity and mortality. Several of these risks are direct consequences of extra-131 
ovarian defects generated by the gene mutations underlying some forms of POI [2]. The clinical 132 
relevance of POI has exponentially increased only very recently, particularly in economically 133 
advanced countries, due to the frequent choice of women to conceive after 30 years of age and 134 
the increased life expectancy.  135 
POI can manifest as pubertal delay and primary amenorrhea (PA) or as secondary amenorrhea 136 
(SA) or oligomenorrhea of >4 months. Recurrence of menses and pregnancies can occur up to 137 
22% of cases with SA up to 4 months [3], but spontaneous resumption of follicle activity is 138 
exceptional in cases with long-lasting SA. The POI-associated hypergonadotropic 139 
hypogonadisms is defined as elevation of follicle stimulating hormone (FSH) (see glossary) ≥ 140 
25 IU/L confirmed twice 30 days apart in women with SA [1]. The ovarian reserve (OR) can be 141 
evaluated by transvaginal ovarian ultrasound (US) with antral follicular count and/or by anti-142 
Müllerian hormone (AMH) determination. Both in PA and SA cases, it is possible to uncover a 143 
certain ovarian reserve by US and AMH measurement [4]. 144 
Low/undetectable AMH indicates a dramatic diminution of the ovarian reserve predicting poor 145 
success of fertility preservation. However, follicular activity and pregnancy were rescued in POI 146 
patients with undetectable serum AMH after in vitro activation (IVA) and auto-transplantation of 147 
fresh tissue [5]. 148 
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Menstrual irregularities, such as oligoamenorrhea or polymenorrhea, can anticipate the onset of 149 
SA, but not as a rule. 150 
Many clinicians are unaware of the advantages of early POI diagnosis and fail to provide 151 
integrated personal care to address all the clinical needs. Here, we review the pathophysiology, 152 
genetics and treatment of POI in order to shed light on: a) the manifestations that should alert 153 
clinicians; and b) the novel multidisciplinary approaches for improved clinical management.  154 
Iatrogenic POI frequently occurs in cancer survivors of young age. A variety of environmental 155 
factors such as infections or pollutants like phthalates, bisphenol A and polycyclic aromatic 156 
hydrocarbons from cigarette smoke, have a harmful impact on reproduction and are implicated in 157 
about 10% of POI [6]. Pollutants can affect ovarian follicles mainly by binding to estrogen or 158 
aryl hydrocarbon receptors, severely affecting follicle growth and viability [7]. Moreover, 159 
pollutants can cause germline epigenetic modifications, thereby accounting  for transgenerational 160 
inheritance of reduced ovarian reserve [8]. About 5-30% of POI may have autoimmune origin 161 
[9], which is of potential interest because an early diagnosis may allow prompt treatment and 162 
eventually prevent damage to the ovarian reserve. 163 
 164 
The incidence of familial cases of premature ovarian failure was reported to vary from 4 to 31%. 165 
[10,11]. Thorough evaluation of alleged affected relatives showed a lower incidence than the 166 
original family history suggested of 12.7% [12]. Pedigree studies on affected families showed a 167 
mode of inheritance suggestive of autosomal dominant or recessive transmission with highly 168 
variable expressivity or X-linked inheritance with incomplete penetrance [13]. Approximately 2-169 
6% of women with sporadic POI have a premutation of the FMR1 gene [14]. Other known 170 
genetic causes are responsible for a small proportion of POIs.  171 
Most causes of POI are unknown. Understanding of the underlying molecular mechanisms is 172 
essential to develop strategies for prevention, early diagnosis and improved management of POI.  173 
 174 
A great leap in the genetics of POI was achieved by the major methodological progress of Next 175 
Generation Sequencing (NGS) and in particular Whole Exome Sequencing (WES). The 176 
knowledge of more than 60 genes has enabled genetic diagnosis by NGS and provided a flow 177 
chart for the diagnosis and treatment of POI. A novel innovative treatment of the infertility of 178 
these patients has recently emerged. 179 
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 180 
ESTABLISHMENT OF THE OVARIAN RESERVE 181 
 182 
Primordial follicles (PF) constitute the entire OR. Mechanisms that regulate the formation of the 183 
PF pool and the rate by which it is used will determine the duration of the fertile lifespan 184 
(Figures 1, 2). OR formation is a similar process in humans and mice, and in recent years, much 185 
insight has been gained into the molecular mechanisms involved. 186 
At 20 weeks of gestation, a pair of human ovaries contains close to 7 million germ cells [15]. A 187 
rapid loss of follicles in fetal life results in about 1-2 million oocytes at birth. Prior to puberty the 188 
number has declined further to 300,000-400,000. During reproductive life, the number declines 189 
steadily until a critical threshold of 1000 primordial follicles is reached [15]. Below this 190 
threshold, ovulations cannot be supported, yielding menopause. 191 
 192 
Oocytes derive from primordial germ cells (PGCs), which emerge from the extraembryonic 193 
mesoderm and migrate to the genital ridge (Figure 1). Upon arrival in the gonad, the PGCs will 194 
yield interconnected oogonia which, together with aggregation of germ cells, create so-called 195 
germ cell cysts [16]. Somatic cell-derived factors, in particular bone morphogenetic factors 196 
(BMPs) and Wnt3/β-catenin, control the commitment, migration and proliferation of PGCs. 197 
These signaling pathways induce the reacquisition of pluripotency, which is driven by Prdm1 198 
and Prdm14. Subsequently, pluripotency genes (Pou5F1 encoding Oct4, Nanog, Klf4, Lin 28a) 199 
and germline specific genes (early genes: Nanos3, Kitlg, Tfapc2, Dppa3; late genes: Ddx4 or 200 
Vasa, Mael, Dazl) play important roles in the migration, proliferation and survival of PGCs [16]. 201 
After cessation of mitosis, the oogonia enter meiosis (13.5 dpc in mouse and asynchronously 202 
10-12 weeks of gestation in humans) and become oocytes (Figures 1 and 2). They will progress 203 
through the initial stages of prophase I until arrest in diplotene stage of prophase I. The initiation 204 
of meiosis is dependent on expression of Dazl, which induces responsiveness to retinoic acid, 205 
which in turn induces Stra8 (stimulated by retinoic acid)-dependent and -independent pathways, 206 
and subsequently the activation of the synaptonemal complex proteins Sycp1, 2, and 3. Recently, 207 
Taf4b was identified as an upstream regulator of several meiotic genes, including Stra8 and 208 
Dazl, in mice and women [17]. Additionally it recently appeared that post-transcriptional 209 
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mechanisms involving the Ythdc2/Meioc complex are mandatory for the proper mitotic/meiotic 210 
transition [18,19].  211 
 212 
The next developmental step in follicle formation is the breakdown of germ cell cysts between 213 
E17.5 and 5 dpp in mice and at mid gestation (10-13 weeks of gestation) in humans (Figure 1). 214 
Upon breakdown pregranulosa cells are recruited to encapsulate a single oocyte to form PF, and 215 
oocytes undergo meiotic arrest. Gdf9, Bmp15, FoxL2, Nobox, Figla, Notch2, and Adam10 216 
include some of the factors that affect the timing of cyst breakdown and differentiation of 217 
pregranulosa cells [20,21]. Furthermore, estrogen signaling plays an inhibitory role in cyst 218 
breakdown [22]. At the cessation of mitosis, the number of oogonia has increased exponentially. 219 
However, it is estimated that during cyst breakdown, two thirds of the oocytes are lost through 220 
programmed cell death, including apoptosis and autophagy [23]. 221 
 222 
Genetic modification in mice has been beneficial to identify the crucial genes in establishment of 223 
the ovarian reserve. Mutations in several of these genes have been identified in women bearing 224 
POI.  225 
 226 
RECENT ADVANCES IN THE GENETICS OF POI IN HUMANS  227 
 228 
The genetic causes of POI are highly heterogeneous with isolated or syndromic forms.  229 
Reproductive and extra-reproductive features of syndromic POI are described in Table 1. The 230 
genes involved are listed in Figures 1-3 and Table 1. 231 
 232 
MEIOSIS, DNA REPAIR AND POI   233 
Mutations of meiotic and DNA repair genes are responsible for syndromic and non-syndromic 234 
POI (Figures 2 and 3). There have been recent major advances in the identification of these 235 
genes as a cause of POI through NGS studies. 236 
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Oocytes enter into and progress through meiosis prophase I during fetal life.  Mutations in 237 
meiotic genes usually impair meiotic progression and trigger oocyte death as evidenced by 238 
several mouse models [24].  239 
During prophase I, meiosis requires the establishment of the synaptonemal complex (SC) and the 240 
generation and repair of DNA double strand breaks (DSB) [25]. Cohesin rings surrounding the 241 
chromosomes contribute to proper formation of the SC. Stromal antigen 3 (STAG3), 242 
Recombination 8 (REC8), Structural Maintenance of Chromosomes 1B (SMC1B) and Radiation 243 
Sensitive 21-Like (RAD21L) encode proteins belonging to the cohesin family and are specific to 244 
meiosis. Exome sequencing revealed that the two copies of STAG3 are inactivated by a 245 
truncating mutation in patients with POI from a consanguineous family [26]. Of note, one patient 246 
had bilateral ovarian tumors. Inactivation of Stag3 in mice impairs meiotic progression and leads 247 
to oocyte death [27]. SMC1B and REC8 have also been proposed to be associated with POI [28]. 248 
The SC is formed by several proteins organized in lateral and central elements [25]. A 249 
homozygous mutation of the Synaptonemal Complex Central Element Protein 1 (SYCE1) was 250 
described in two sisters with POI in a consanguineous family [29], being consistent with 251 
infertility observed in animal models [30]. 252 
Mini Chromosome Maintenance 8 and 9 are helicase members of the MCM family. MCM8-9 253 
complex is required for homologous recombination (HR)-mediated repair of DSB, facilitating 254 
DNA resection by the MRN complex [31]. Lack of Mcm8 or Mcm9 in mice induces meiotic 255 
defects, oocyte degeneration and ovarian tumors. Regarding MCM8, the analysis of three 256 
consanguineous sisters with hypothyroidism and POI revealed the presence of a pathogenic 257 
variant [32]. The study of several other consanguineous families allowed the identification of 258 
homozygous variants for MCM8 and MCM9 in the affected patients[33–36]. 259 
For MCM8 and MCM9, the repair of chromosomal breaks in fibroblasts or lymphocytes of the 260 
patients was found altered [32,33].  261 
Meiotic DSB repair requires the loading of two recombinases RAD51 and its meiotic paralog 262 
DMC1 on DNA. The activities of DMC1 and RAD51 are regulated by many factors including 263 
homologous-pairing protein 2 homolog (HOP2/PSMC3IP). Only one homozygous mutation in 264 
DMC1 has been reported in women with POI [37]. The study of a Palestinian family using 265 
homozygosity mapping and NGS allowed the detection of a homozygous microdeletion in the 266 
PSMC3IP gene [38]. The possibility of a meiotic defect in the patients studied was not examined 267 
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directly. 268 
The recombination intermediates need to be stabilised to promote the formation of crossovers. 269 
This step requires helicases such as HFM1 and the dimer MSH4-MSH5. Exome sequencing has 270 
uncovered composite heterozygous mutations in HFM1 in a cohort of patients with sporadic POI 271 
and secondary amenorrhea [39,40], in agreement with the phenotype of the hfm1-/- mice. Exome 272 
sequencing recently identified a deleterious homozygous donor splice-site mutation in MSH4 in a 273 
case of familial POI. This mutation was associated with the generation of internally deleted 274 
MSH4 protein [41]. Similarly, a homozygous mutation in MSH5 in two sisters with POI has 275 
recently been reported [42]. The adverse effect of this mutation was confirmed in a mouse model 276 
and proven to impair DNA repair.  277 
The final step of recombination is the resolution of recombination intermediates. The resolution 278 
of the double Holliday junctions (dHj) is believed to rely on the heterodimer MLH1-MLH3, and 279 
the exonuclease EXO1. Mice lacking either Mlh1 or Mlh3 are sterile. Human mutations reported 280 
in MLH1 are largely associated with colorectal cancer and Lynch syndrome with no systematic 281 
impact on fertility. 282 
Three RecQ helicases, namely BLM (Bloom syndrome), RECQL4 (RecQ protein-like 4) and 283 
WRN (Werner syndrome) are proposed to be involved in meiotic recombination albeit their 284 
function in mammals is not fully elucidated. These RecQ helicases are also mutated in human 285 
syndromes manifesting in premature aging, cancer and often POI or reduced fertility [43–45]. 286 
 287 
Cockayne Syndrome B (CSB/ERCC6) encodes a protein involved in DNA repair. A heterozygous 288 
mutation in the CSB-piggyBac transposable element derived 3 (PGBD3) fusion gene-induced 289 
POI with the mutated protein exhibiting an altered response to DNA damage [46].  290 
Lastly, though meiotic DSB repair appears to rely on homologous recombination, a second 291 
process for DSB repair, the non-homologous end-joining (NHEJ), allows the direct ligation of 292 
broken DNA ends to each other. X-ray repair cross-complementing protein 4 (XRCC4) and 293 
Ligase 4 (LIG4) are two proteins absolutely required for NHEJ. Syndromic POI was reported in 294 
a female patient with homozygous single nucleotide variant in the XRCC4 gene [47]. POI was 295 
reported in two patients with biallelic truncating mutations in the LIG4 gene [48]. These patients 296 
display short stature, microcephaly and genomic instability or hypersensitivity to radiation. 297 
Similarly, another important DNA repair pathway, the Fanconi anemia (FANC) pathway, exists 298 
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in numerous progenitor cells, including the germline. This pathway employs at least 20 proteins 299 
including those encoded by the FANCA, FANC and FANCG genes, and were associated with 300 
POI [49]. Mouse models for several Fanc genes (a, c, d, e, f, g, i, m, n, o, p) evidenced gonadal 301 
hypoplasia with ovaries showing follicle depletion [50]. This appears to be due to reduced 302 
primordial germ cell numbers though meiotic roles are also possible. Very recently a 303 
homozygous FANCM mutation was shown to underlie a familial case of non-syndromic POI 304 
[51]. FANCM biallelic mutations predispose to cancer, in particular early-onset breast cancer in 305 
females, and chemosensitivity [52–54]. These findings clearly support a genetic link between 306 
infertility and DNA-repair/cancer genes. 307 
The recent identification of a genetic link between POI and tumor/cancer susceptibility 308 
genes (STAG3, MCM9, FANCM) makes the genetic diagnosis of all isolated cases of 309 
unexplained POI necessary, to perform an enhanced genetic counseling and long-term follow-up. 310 
Indeed POI patients can harbor mutations in such ‘cancer susceptibility’ genes. The large number 311 
of genes potentially involved will make these families among the most important involved in 312 
POI. 313 
 314 
GENES INVOLVED IN SYNDROMIC POI (Figures 2, 3 and Table 1)  315 
The clinical presentations of syndromic POI are highly variable and are presented in Table 1.   316 
 317 
Perrault syndrome (PS) 318 
Perrault syndrome (PS) is a genetically heterogeneous autosomal recessive syndrome mainly 319 
characterized by ovarian dysfunction and sensorineural deafness (see Table 1). Recently, a 320 
growing number of genes involved in PS was identified by NGS. These genes are implicated in 321 
mitochondrial functions or metabolism. In mouse models genetic changes that cause perturbation 322 
in mitochondrial protein translation lead to hearing loss as a result of tissue-specific apoptosis 323 
[55]. Given the role of apoptosis in ovarian development, inappropriately timed apoptosis may 324 
also lead to POI. HARS2 [56] and LARS2 [57,58]  encode mitochondrial histidyl or leucyl-tRNA 325 
synthetases involved in translation of mitochondrially encoded genes. CLPP encodes a highly 326 
conserved endopeptidase component of a mitochondrial ATP-dependent proteolytic complex, 327 
involved in degradation of unfolded or misfolded polypeptides [59–61]. C10orf2 encodes 328 
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Twinkle, a mitochondrial primase-helicase essential for mitochondrial DNA replication [62,63], 329 
yielding a mitochondrial DNA depletion syndrome and progressive external ophthalmoplegia. 330 
Very recently mutations of ERAL1 and KIAA0391 were involved in PS. ERAL1 protein binds to 331 
the mitochondrial 12S rRNA and is involved in assembly of the small mitochondrial ribosomal 332 
subunit affecting mitochondrial respiration and function [64]. KIAA091 encodes RNase P 333 
(PRORP) the metallonuclease subunit of the mitochondrial RNase P complex responsible for the 334 
5‘-end processing of mitochondrial precursor tRNAs [65]. 335 
Apart from mitochondrial functions, mutations in a multifunctional peroxisomal enzyme 336 
involved in fatty acid ß-oxidation and steroid metabolism, 17β-hydroxysteroid dehydrogenase 337 
type 4 [HSD17B4, also known as D-bifunctional protein (DBP)] also cause PS [66–68].  338 
Mutations of this gene were already identified in autosomal recessive mode in a severe disorder 339 
of peroxisomal fatty acid β-oxidation.  340 
A combination of two homozygous mutations leading to a coincidental PS, one in CLDN14 341 
involved in deafness and the other in shugoshin-like 2a (SGO2) encoding shugoshin2, likely 342 
involved in POI, have been described [69]. In the mouse SGO2 maintains during meiosis the 343 
integrity of the cohesion complex that tethers sister chromatids. Unsolved cases of PS persist, 344 
indicating that novel genes will still be discovered [70,71].  345 
 346 
Premature aging syndromes 347 
Laminopathy due to mutations in LMNA encoding a nuclear envelope protein includes ovarian 348 
failure and premature aging. The Malouf syndrome belongs to this condition [72]. The 349 
Hutchinson-Gilford Progeria Syndrome (HGPS) [73], caused by aberrant splicing of the LMNA 350 
gene and expression of a mutant product called progerin, comprises premature aging and 351 
lipodystrophies.  Sometimes both syndromes occur together [73]. 352 
GAPO syndrome, another form of premature aging and premature follicle depletion, is caused by 353 
mutations of the anthrax toxin receptor 1 gene ANTXR1 [74]. The protein has been involved in 354 
cell attachment and migration. Additionally, it allows the interaction of cells and several 355 
components of the extracellular matrix by binding extracellular ligands with the actin of 356 
cytoskeleton. 357 
 358 
Neurosensory syndromes  359 
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Leukoencephalopathies are also a heterogeneous group of disorders associated with vanishing 360 
white matter (VWM) and in a subset POI yielding ovarioleukodystrophy. Mutations of a specific 361 
mitochondrial alanine aminoacyl-tRNA synthetase, AARS2, have been involved [75,76]. Another 362 
group of genes involved is EIF2B1 to EIF2B5 which encode the five subunits of the eukaryotic 363 
initiation factor 2B [77].  364 
Mutations in RCBTB1 [78] are present in a syndrome including inherited retinal dystrophy and 365 
POI. RCBTB1 is involved in ubiquitination, more specifically as a CUL3 substrate adaptor 366 
involved in stress-response to combat oxidative or electrophilic insults. 367 
Mutations of the nuclear gene POLG encoding a mitochondrial DNA polymerase gamma can 368 
lead to POI with autosomal dominant progressive external ophthalmoplegia [79].  369 
Defects in the respiratory chain or mitochondrial ATP synthase (complex V) result in 370 
mitochondrial dysfunction and defective energy production. Mutations of MT-ATP6/8 encoding 371 
two of the subunits of complex V are associated with a syndrome including cerebellar ataxia, 372 
peripheral neuropathy, diabetes mellitus and POI [80]. 373 
 374 
Skeletal syndromes 375 
POI can occur in some skeletal syndromes such as Demirhan syndrome caused by mutations in 376 
BMPR1B [81].  377 
Another condition including proximal synphalangism and POI is caused by mutations in NOG 378 
[82]. NOG protein is expressed in the ovaries and interacts with BMP which plays an important 379 
role in ovarian function.  380 
 381 
GENES ASSOCIATED WITH NON-SYNDROMIC POI (Figures 2, 3) 382 
 383 
REGULATION OF PRIMORDIAL FOLLICLE RECRUITMENT 384 
 385 
The majority of PF will remain dormant until stimulatory signals or a break from inhibitory 386 
signals induces activation. PF recruitment is initiated in mice after birth at PND 4-5, and in 387 
humans at 17 weeks of gestation (Figure 1). 388 
Various oocyte-expressed signaling and/or transcription factors have been identified to maintain 389 
the quiescent state (Foxo3, Lhx8) or, in contrast, to activate PF growth (Sohlh1, Sohlh2, Nobox) 390 
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[83] (Figure 2). Interestingly, Foxo3 and Lhx8 are the effectors of the PI3K/Akt signaling 391 
pathway [84]. Targeted (oocyte-specific) deletion of stimulating factors (Kit, Pdpk1, Rptor, 392 
Rps6) of this pathway blocks follicular activation and induces PF apoptosis, whereas loss of the 393 
inhibiting factors (Pten, Cdkn1b, Tsc1, Tsc2, Stk11) results in premature and global activation of 394 
PF [85] (Figure 2). 395 
A characteristic of PF activation is the transition of squamous pre-granulosa cells to cuboidal 396 
granulosa cells. Failure thereof results in an arrest at the primordial stage followed by oocyte 397 
death and follicular depletion, as shown in FoxL2 knockout mice [86]. AMH, expressed during 398 
this transition, inhibits PF activation since Amh knockout mice display an accelerated exhaustion 399 
of the pool [87]. Several additional growth factors have been shown to activate primordial 400 
follicle recruitment (Figure 2).  401 
 402 
REGULATION OF FOLLICLE GROWTH 403 
 404 
Gonadotropin-independent phase: role of ovarian growth factors 405 
Early follicle growth up to the large preantral stage is independent of gonadotropins in rodents 406 
and relies on intraovarian factors (Figure 2). It requires a coordinated dialog between the oocyte 407 
and granulosa cells in which gap junctions, and SMAD and PI3K/Akt pathways are important. 408 
The discovery that follicles in ovaries of Gdf9 knockout mice fail to develop beyond the primary 409 
stage was the first of a series showing the importance of factors involving SMAD signaling 410 
pathway in follicle development [88]. Furthermore, in the oocyte-knockout of  Furin, a pro-411 
hormone convertase responsible for proteolytic cleavage of TGFβ family members, follicle 412 
growth is arrested at the secondary stage [89]. Likewise, inhibition of the PI3K/Akt pathway by 413 
Kit or Kitlg deletions leads to the blockage of follicular growth at the primary follicle stage. 414 
Using targeted deletion or activation of Igf1, Igf1r, Irs2, Rictor or Foxo3, it was shown that the 415 
PI3K-Akt signaling pathway not only plays a role in primordial follicle activation, but also in 416 
follicle survival and development beyond the primary stage [90,91] (Figure 2). 417 
 418 
Gonadotropin-dependent phase: role of gonadotropins 419 
The progression through final stages of follicle development depends on the gonadotropins FSH 420 
and LH (Figure 2). The threshold for FSH sensitivity is determined by interplay between various 421 
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stimulatory and inhibitory growth factors, such as IGF1 and various TGFβ family members 422 
tipping the balance to either follicle survival or atresia. Deletion of the Fshr yields an enhanced 423 
rate of atresia and follicles fail to progress to the antral stage [92]. Targeted deletion of the non-424 
canonical progesterone receptor Pgrmc1 in granulosa cells suppressed antral follicle 425 
development and increased atresia [93]. Finally, LH action is indispensable for ovulation, 426 
meiotic resumption of the oocytes, and cumulus expansion. Loss of LH action therefore also 427 
results in infertility as follicle development is blocked at the antral stage [94]. In the absence of 428 
sex steroid action, the final stages of follicle development show abnormalities leading to 429 
follicular arrest as illustrated in mouse models lacking (cell-specific) androgen or estrogen 430 
function [95,96]. 431 
 432 
Defects in human genes in non syndromic POI 433 
 434 
Interestingly there is an overlap between genes involved in the onset of puberty, normal 435 
reproductive aging and POI [97]. We will present only recent data or selected examples of genes 436 
that illustrate the precaution that must be taken in the interpretation of genetic data and 437 
comparison with animal models.  438 
 439 
Genes involved in establishment of the primordial follicle pool and maturation to primary 440 
follicles 441 
Heterozygous variants of SOHLH1 and SOHLH2 have been found in POI [98].  Interestingly 442 
two families harbouring a homozygous single-base deletion in the coding region or a premature 443 
stop codon of SOHLH1 [99] had primary amenorrhea, lack of secondary sex characteristics and 444 
non-visualized ovaries. 445 
 446 
A recessive missense mutation in Nucleoporin-107 was identified in a consanguineous family of 447 
Palestinian origin [100]. NUP107 is a component of the nuclear pore complex, and the NUP107-448 
associated protein SEH1 is required for oogenesis in Drosophila. In Drosophila, Nup107 449 
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knockdown in somatic gonadal cells resulted in female sterility, whereas males were fully fertile. 450 
Nup107 mutations may compromise the meiotic DNA damage response, leading to oocyte death. 451 
 452 
A heterozygous stop codon was identified in the eukaryotic translation initiation factor 4E 453 
nuclear import factor 1 gene eIF4ENIF1 in familial POI with dominant inheritance in three 454 
generations [101]. The gene plays an important role in oocyte development in organisms from 455 
Drosophila to mice. 456 
Heterozygous mutations of the Newborn ovary homeobox (NOBOX) transcription factor have 457 
been reported in women with sporadic POI [28,102,103]. Contrasting with the knock-out mouse 458 
model which displays accelerated postnatal oocyte loss due to a defect in germ cell cyst 459 
breakdown [104], patients with NOBOX mutations may have primary or secondary amenorrhea 460 
with follicles detected in adulthood in the ovaries by histology [102]. This may be due to the fact 461 
that the human mutations caused only partial loss of function in vitro. Functional studies are thus 462 
critical before any comparison with animal models and before any conclusion on the human 463 
physiological role of a gene can be established. Interestingly, a prevalence of 5.6 and 6.2% of 464 
heterozygous mutations has been detected in different cohorts making this gene potentially one 465 
of the most frequent causes of POI in humans, provided that causality of the heterozygous 466 
variants is proven. Recently, a homozygous truncated variant of NOBOX has been described 467 
[105], with complete loss of function in vitro in patients with primary amenorrhea, but with no 468 
ovarian phenotype. Fertility of the heterozygous mother excludes a mechanism of 469 
haploinsufficiency as previously proposed. 470 
 471 
Genes involved in the maturation and growth from primary to ovulatory follicles 472 
The two steroid hormone receptors, for estrogens (ESR1) and androgens (AR), are positive 473 
regulators of follicular maturation. Two families with homozygous mutations of ESR1 have been 474 
described. The probands had primary amenorrhea without breast development, very high 475 
estrogen plasma concentrations and multicystic ovaries [106,107]. Functional studies reveal 476 
altered estrogen signaling. 477 
Interestingly, a continuum of phenotypes is associated with FSHR mutations varying from 478 
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absence of pubertal maturation to normal breast development with secondary amenorrhea, 479 
according to severity of the receptor inactivation [108–111]. The first mutation described in the 480 
Finnish population was associated with the existence of preantral or rare antral follicles in the 481 
ovaries [108]. However functional studies have shown that it was a partial loss of function 482 
mutation [112]. A complete loss of function mutation of the FSHR has also been described, 483 
causing primary amenorrhea and complete block of follicular maturation after the primary stage 484 
[113]. Remarkably there was an increased density of small follicles when compared to an age-485 
matched woman. Thus, the gonadotropin-dependent growth phase in humans starts at the 486 
primary follicle stage contrary to rodents in which preantral follicles are observed in ovaries of 487 
mice deficient of Fshb or Fshr (see above). Thus caution must be taken before extrapolating data 488 
from mouse models to humans. Partial mutations of the FSHR are associated with secondary 489 
amenorrhea and the presence of different-sized antral follicles depending on severity of the 490 
mutation [114]. Of note, there is a correlation between the phenotype of the patients and the 491 
molecular studies. Because of the existence of follicles in the ovaries in vitro maturation may be 492 
obtained and fertility restored [115] and see below. 493 
Mutations in the other gonadotropin receptor gene, LHCGR, cause POI with secondary 494 
amenorrhea, anovulation and recurrent cysts formation. In the affected families disorders of sex 495 
differentiation are found in male relatives with hypogonadism due to Leydig cell hypoplasia 496 
[116,117]. 497 
The first involvement of BMP15 in POI was reported in an Italian family with 46,XX ovarian 498 
dysgenesis [118]. Since then, several heterozygous and one homozygous BMP15 variants were 499 
associated with primary or secondary amenorrhea, but streak ovaries were found without 500 
follicles by ultrasound, which was interpreted as premature depletion of the ovarian reserve 501 
[118]. Functional studies support impaired production of the mature protein or a dominant 502 
negative effect in some cases [118]. However, most of the variants detected occur in 503 
heterozygous state, and BMP15 haploinsufficiency was proposed to have a predisposing impact 504 
for POI. It was also proposed that reduced BMP15 dosage would contribute to the ovarian 505 
phenotype of Turner syndrome patients [119]. These conclusions were challenged by a very 506 
recent work on a family with a BMP15 knockout-like effect [120], with both parents bearing 507 
deletions in the proregion of the BMP15 precursor. The heterozygous mother conceived 508 
normally and had three children. Thus, it seems that haploinsufficiency is not involved in 509 
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humans. Most of the mutations of BMP15 described were heterozygous and a mechanism of 510 
haploinsufficiency or a dominant negative effect was suspected but most often not demonstrated, 511 
making it impossible to implicate the corresponding gene as the unique cause of POI. Additional 512 
genetic mutations in an oligogenic mode of inheritance and/or environmental factors must be 513 
involved. Despite streak ovaries, AMH was initially detectable in the two POI sisters bearing 514 
both deletions of BMP15, supporting the presence of an ovarian reserve [120].  Five years later, 515 
however, AMH was not detected in both sisters, probably because of exhaustion of the 516 
primordial follicle pool, and one sister had received an egg donation.  517 
In case POI is due to a block in follicular maturation urgent fertility preservation is thus needed 518 
to avoid follicular atresia.  519 
 520 
A recent study showed a homozygous single base deletion in the coding region of GDF9 in POI 521 
with PA [121] confirming the causative role of this gene.  522 
 523 
 524 
INNOVATIVE TREATMENTS FOR POI  525 
 526 
The most frequent therapeutic approach of infertility of POI patients is embryo transfer from 527 
donated oocytes. Given the complexity of this therapeutic approach, couples requiring oocyte 528 
donation should discuss its medical, ethical, legal and psychological aspects with medical 529 
experts. Recently, a new innovative fertility treatment has been developed for POI (Figure 4). 530 
 531 
Premature activation of primordial follicles caused by chemotherapy, particularly 532 
cyclophosphamide, is a significant cause of the disappearance of follicles from the ovaries. 533 
Fertility preservation through tissue cryopreservation before chemotherapy is therefore an 534 
important method to prevent POI [122]. Post treatment, the tissue can be auto-transplanted. 535 
Infants have been born as a result of the technique. 536 
For cancer patients at high risk of re-introduction of the malignancy, such as leukemia, in vitro 537 
maturation of follicles all the way to metaphase II oocytes is a much needed therapy that still 538 
remains to be developed.   539 
 540 
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In early stages of ovarian insufficiency there are primordial follicles left in the ovaries. Hence, 541 
cryopreservation of ovarian tissue as fertility preservation should be carried out as soon as the 542 
risk of follicular decrease has been identified. Although, these primordial follicles are inactive 543 
Hovatta et al. [123] showed that human ovarian follicles can be activated when ovarian tissue is 544 
cut into small pieces and placed in organ culture. Recently, Hippo signaling was identified as the 545 
regulatory factor in this activation [5,124]. When residual follicles in ovarian tissue from POI 546 
patients were stimulated by cutting the tissue into small pieces, and subsequently exposed to 547 
phosphatase and tensin homolog (PTEN) inhibitors and protein kinase B (Akt) activators prior to 548 
transplantation, full oocyte maturation can be achieved [125] (Figure 4). Of note, PTEN is also 549 
an important tumor-suppressor, and therefore its inactivation in vivo might be risky. After in 550 
vitro activation (IVA), the follicles have to be stimulated to grow, and FSH stimulation is used 551 
in a similar manner as in ovulation induction or before in vitro fertilization treatments. 552 
Transplantation of the ovarian tissue back to patients after IVA has been performed and healthy 553 
infants have been born (Figure 4). This IVA method is useful for those patients who may have 554 
residual follicles left in their ovaries (See flow chart for POI diagnosis and treatment Figure 5).  555 
 556 
Ultimately recent technological developments with induced pluripotent stem cells (iPS) allow the 557 
reconstitution of complete oogenesis [126]. Although this has currently only been achieved in the 558 
mouse, advances with human cells make it now conceivable for modeling POI and would prove 559 
invaluable for supporting genetic diagnosis. In specific cases (e.g altered follicle recruitment or 560 
growth), such models may prove useful for drug screening and selecting the most appropriate 561 
treatment. 562 
Other technological developments such as the tissue engineering to generate ovarian implants 563 
able to restore fertility are promising leads that may help restoring fertility [127]. 564 
  565 
CONCLUDING REMARKS AND FUTURE PERSPECTIVES:  566 
 567 
Taken together, the vast technological advancements have provided valuable new information 568 
on the molecular pathophysiology of POI and its new diagnosis and treatment opportunities. 569 
Information derived from recent genetic studies has improved the accuracy of POI diagnosis and 570 
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may reveal new targets for the treatment of infertility or for contraception in the future. Because 571 
of its increased non-reproductive morbidity and mortality (e.g. autoimmunity and tumors) POI 572 
should be followed by a multidisciplinary team. The very recent identification of a link between 573 
POI and tumor susceptibility makes the genetic diagnosis of all isolated cases of unexplained 574 
POI necessary. Also, POI as a genetic disorder becomes amenable to innovative therapies unlike 575 
most other genetic diseases. This obviously necessitates the presence of remnant ovarian reserve 576 
that has to be evaluated besides conventional methods by genetic studies (Figure 5). Indeed the 577 
key question is: what is the state of the follicular pool in the POI patient? The mutated gene may 578 
provide important information on the ovarian reserve depending on its level of action during 579 
either establishment and/or maintenance of the follicular pool, or follicular growth. This belongs 580 
to the questions that will need to be answered in the future (see outstanding questions box). 581 
 582 
 583 
FIGURE LEGENDS  584 
 585 
Figure 1: Formation of the ovarian reserve in humans and mice. 586 
 587 
Top: Chronology of female germ cells development from primordial germ cell (PGC) 588 
specification until follicle formation (purple). Appearance of oogonia and meiotic cells are 589 
defined respectively by the blue and red lines [weeks post fertilization (wpf), days post 590 
conception (dpc), days post-partum (dpp)]. Middle: Schematic presentation of the various germ 591 
cell stages. From left to right, migratory PGCs, oogonia, pre-leptotene, leptotene, zygotene, 592 
pachytene and diplotene arrested oocytes in primordial and growing (primary) follicles are 593 
presented in blue. Key signaling pathways regulating PGC specification, meiotic entry and 594 
follicle activation are provided in green. BMPs, bone morphogenic proteins; PRDM, PR domain 595 
containing 1, with ZNF domain (PRDM1/BLIMP1); RA, retinoic acid; STRA8, stimulated by 596 
retinoic acid 8; CYP26B1, cytochrome P450, family 26, subfamily B, polypeptide 1; KITL, kit 597 
ligand; FOXO3, forkhead box O3; PI3K, phosphoinositide-3-kinase; PTEN, phosphatase and 598 
tensin homolog. Bottom: Frequently used markers of the various germ cell stages. POU5F1 599 
(OCT4), POU class 5 homeobox 1 and TFAP2C (AP2 γ) are retrieved in PGC and oogonia with 600 
stem cell potential. DAZL, deleted in azoospermia-like and DDX4 (VASA), DEAD box 601 
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polypeptide 4, mark the gametogenic competency acquired when mouse germ cells colonize the 602 
gonad and later during oogonial differentiation in the human ovary. STRA8 is expressed at the 603 
mitotic/meiotic switch, in pre-leptotene stage and SYCP3 is a synaptonemal complex protein that 604 
labels the axes of the chromosomes during meiotic prophase I. NOBOX, NOBOX oogenesis 605 
homeobox, and TP63, tumor protein 63, are retrieved in the nuclei of diplotene-arrested oocytes 606 
enclosed into follicles. 607 
 608 
Figure 2: Human genes associated with POI and their physiological importance in 609 
oogenesis, folliculogenesis and other functions.  610 
Genes with in vivo mutations associated with POI in human and their physiological importance 611 
in ovarian function are indicated. Oogenesis and folliculogenic processes are represented by a 612 
transit between different compartmental stages depicted as boxes containing the cell populations. 613 
At each stage of oogenesis and folliculogenesis, an important part of the germ cells will die by 614 
apoptosis, depicted by a concomitant decrease in boxes sizes. The first compartment (yellow 615 
box) corresponds to the primordial germ cells (PGC) when they differentiate into oogonia, the 616 
second compartment (green box) corresponds to follicle formation, which involves meiosis and 617 
follicular assembly processes and ends with establishment of the ovarian reserve of primordial 618 
follicles (pink box). From this reserve, follicular activation leads to the formation of primary 619 
follicles (light blue box). Then the growing follicles can reach the antral stage (dark blue box) 620 
and ovulate, or degenerate by atresia. Genes whose mutations are associated with POI are 621 
indicated at each stage of these developmental processes. The involvement of each gene at a 622 
specific stage of ovarian or follicular development is based on in vivo (presence/absence of 623 
follicles in biopsy samples, detection of antral follicles using ovarian ultrasound scanning or 624 
AMH measurements in women carrying mutations) or/and in vitro observations (culture 625 
experiments using human ovarian cortex or granulosa cells). For genes depicted in italic, 626 
information on their stage specific role is only available from mouse models. Genes associated 627 
with POI for which the stage-specific role is unknown are listed in the box, with their biological 628 
function (green font). The stimulating and inhibiting factors are depicted in black and red font, 629 
respectively. See text for references and [13]. 630 
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 631 
Figure 3: Female infertility, meiotic recombination and DNA repair 632 
The various steps of meiotic recombination and specific genes involved (non-exhaustive, middle panel) 633 
are presented in the middle panel. Genes suspected in POI cases are in bold. Left panel shows the 634 
structure of the synaptonemal complex required for completing recombination. Right panel presents 635 
representative germ cells at oogonial (A), leptotene (B), zygotene (C), pachytene (D) and diplotene 636 
(primordial follicle, E) stages respectively from human ovaries at 8, 12, 15, 21 and 27 weeks post-637 
fertilization. 638 
 639 
Figure 4: In vitro activation of dormant follicles 640 
Ovarian cortical tissue is laparoscopically biopsied from the woman undergoing POI. The tissue 641 
is cut to slices for activating Hippo signaling and initiation of follicular growth. Sliced tissue is 642 
then activated using a PTEN inhibitor or AKT stimulator in vitro for 24 hours. Thereafter the 643 
tissue pieces can be transplanted back to the ovary of the donor woman. The activated follicles 644 
are stimulated using human recombinant FSH for 6-10 days, until 15-17 mm size antral follicles 645 
are seen by ultrasonography. The woman will be given human recombinant LH to induce the 646 
final maturation of the oocytes. The oocytes are collected 36 hours later using transvaginal 647 
ultrasound-guided needle aspiration. They are injected by intracytoplasmic sperm injection 648 
(ICSI) with sperms from the partner. The embryos are cultured for 3 to 5 days, and the 649 
morphologically best embryo will be transferred to the intravaginal progesterone-treated female 650 
partner’s womb, and the rest of the embryos are cryo-stored for future transfers.   651 
 652 
Figure 5: Flow chart for POI diagnosis and treatment  653 
After the initial diagnosis of POI, family investigation and evaluation of the follicular reserve by 654 
AMH assay and antral follicular count (AFC) are performed. Specific causes are eliminated. In 655 
case of unexplained POI karyotype and FMR1 study are performed. In all cases hormonal 656 
treatment has to be started. In isolated POI array CGH (aCGH) or NGS can highlight defects in 657 
genes involved in ovarian differentiation or in the establishment of the follicular pool. This 658 
together with the undetectable ovarian reserve will lead to genetic counseling in the patient and 659 
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relatives and therapeutic counseling for the patient’s infertility by a multidisciplinary team. If 660 
there is a wish to conceive egg donation will be performed. In case there is a detectable ovarian 661 
reserve and/or a defect in genes involved in follicular maturation genetic counselling will be 662 
performed in the patient and relatives and therapeutic counseling will lead to fertility 663 
preservation. In the future in vitro activation of small follicles (IVA) might be performed. In 664 
syndromic POI NGS of specific genes will be performed according to the clinical phenotype of 665 
the patient. Specific treatment of associated symptoms is needed. 666 
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TABLE 1: Clinical presentations of syndromic POI 667 
 
Diagnosis 
 
Menstrual 
history 
 
Ovarian phenotype 
 
Particular features 
 
OMIM Gene(s) 
involved 
WT1-related XX-DSD PA or SA Streak gonads  
partial ovarian dysgenesis  
Nephropathy, diaphragmatic hernia #194070 WT1 
SF1-related XX-DSD PA or SA Streak gonads  
partial ovarian dysgenesis 
Adrenal insufficiency #612964 NR5A1/SF1 
BPES PA or SA Rare or absent follicles  Blepharophimosis, ptosis, epicanthus inversus #110100  
FMR1 premutation SA Follicle depletion X linked mental retardation in family. Fragile X tremor/ataxia 
syndrome 
#300624 FMR1 
Autoimmune 
Polyendocrinopathy 
Syndrome. APS-PGA 
type 1 
PA or SA Autoimmune oophoritis Addison disease, candidiasis, vitiligo, hypoparathyroidism, 
diabetes mellitus,  hepatitis, malabsorption, keratopathy, alopecia 
#240300 AIRE 
Autoimmune APS-
PGA type 3 
 Autoimmune oophoritis Autoimmune thyroid disease, atrophic gastritis, vitiligo   
Pseudohypopara 
thyroidism 
SA Follicular cysts but no corpora 
lutea in one case 
Brachydactyly, short stature, hypocalcemia and 
hyperphosphatemia, hypothyroidism, obesity 
#103580 GNAS 
Galactosemia PA Streak ovaries or few non 
maturated follicles 
Neonatal jaundice, failure to thrive, cirrhosis, cataract, intellectual 
disability, food intolerance, hypoglycemia, renal dysfunction. 
#230400 GALT 
Disorders of 
glycosylation 
(CDG1A) 
PA Absent ovaries in some 
patients by US or laparoscopy 
Growth retardation, microcephaly, encephalopathy, peripheral 
neuropathy, retinitis pigmentosa, cardiac myopathy, 
hepatomegaly, nephrotic syndrome, psychomotor retardation 
#212065 PMM2 
Ataxia telangiectasia  PA  Cerebellar ataxia, telangiectasia, recurrent infections, 
malignancies and increased levels of alpha fetoprotein. 
 
#208900 ATM 
Nijmegen breakage 
syndrome 
PA or SA Streak gonads, small ovaries Prenatal growth retardation, progressive mental deterioration, 
microcephaly, recurrent infections,  increased risk for neoplasias 
#251260 NBN 
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such as lymphoma.  
 
Fanconi anemia PA or SA Decreased number of 
primordial follicles 
Pancytopenia, small stature, microcephaly, ear anomalies, heart 
defects, kidney malformations, radial aplasia and thumb 
deformities, intellectual disability, café-au lait-spots 
#227650 
#227645 
#614082 
FANCA 
FANCC 
FANCG 
XRCC4-related 
disorder 
SA  Short stature, microcephaly, developmental delay, diabetes 
mellitus 
#616541 XRCC4 
Bloom syndrome SA Possibly accelerated follicular 
atresia 
Premature aging with chromosomal instability, short stature, skin 
rashes and telangiectatic skin on sun-exposed areas, increased risk 
for neoplasias, immunodeficiency 
#210900 BLM 
Werner syndrome SA Possibly accelerated follicular 
atresia 
Premature aging with chromosomal instability , pre and postnatal 
growth deficiency, sclerodermic skin changes, cataract, 
arteriosclerosis, increased cancer risk, diabetes mellitus 
#277700 WRN 
Rothmund-Thomson 
syndrome 
SA Gonadotropin resistance Short stature, cataract, saddle nose, teeth anomalies, premature 
graying of hair 
#268400 RECQL4 
Hutchinson-Gilford 
progeria 
SA Diminished follicular reserve Progeria, short stature, low body weight, early loss of hair, 
lipodystrophy, scleroderma, decreased joint mobility, osteolysis, 
cardiomyopathy 
#176670 LMNA 
GAPO SA Follicle depletion Growth retardation, alopecia, pseudoanodontia, optic atrophy, 
high forehead, midface hypoplasia 
#230740 ANTXR1 
Perrault syndrome PA , SA Streak ovaries, 
lack of ovaries, 
small ovaries 
Deafness 
Neurologic symptoms in PRLTS1, PRLTS3 and PRLTS5 
#233400 
#614926 
#614129 
#615300 
#616138 
HSD17B4, 
HARS2, 
LARS2 
CLPP 
C10orf2, 
CLDN14+ 
SGO2 
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KIAA0391 
ERAL1 
Woodhouse-Sakati 
syndrome 
PA Streak ovaries Alopecia, deafness, hypogonadism, diabetes, hypogonadism, 
intellectual disability 
#241080 C2orf37 
Vanishing white 
matter disease 
Ovarioleukodystrophy 
 
SA Ovarioleukodystrophy 
streak ovaries 
Progressive cerebellar ataxia, spasticity, cognitive impairment 
with white matter lesions on brain imaging. Onset from early 
infancy to adulthood 
#603896 
#615889 
EIF2B 
AARS2 
Retinal dystrophy with 
or without extraocular 
anomalies 
SA  Retinal dystrophy, goiter, intellectual disability, hypogonadism #617175 RCBTB1 
Progressive external 
ophthalmoplegia 
SA Diminished follicle reserve Ptosis, progressive external ophthalmoplegia , sensorineural 
hearing loss, axonal neuropathy, muscle weakness, ataxia, 
dysarthria, dysphagia and late onset Parkinsonism 
#157640 POLG 
Acromesomelic 
chondrodysplasia with 
genital anomalies 
PA  Severe brachydactyly with radial deviation of the fingers, ulnar 
deviation of the hands, fusion of the carpal/tarsal bones, aplasia of 
the fibula, bilateral clubfeet with small broad feet and short toes 
#609441 BMPR1B 
Interphalangeal joint 
synostosis 
SA  Symphalangism, hearing loss #185800 NOG 
 PA, primary amenorrhea; SA, secondary amenorrhea, DSD: disorder of sexual differentiation. See text for references and [13].668 
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